Abstract
Over the past few years we have begun to accept a concept of carcinogenesis in which a series of mutations in important genes leads to the development of the fully fledged invasive phenotype of cancer. At the same time we have attempted, not always with success, to correlate these mutational events with the morphological pre-neoplastic lesions which have long been recognized Thus, in the colon, we subscribe to the view that most carcinomas arise from a pre-existing non-invasive lesion, the adenoma. Later research showed that the adenoma itself had a precursor lesion - the so-called aberrant crypt focus. It is now appreciated that the mutations which are associated with aberrant crypt foci and adenomas in the colon are heterogeneous, and that while we still accept the concept of sequential, mutation events leading to carcinoma, we accept that the order and timing of these events may vary, and that the mutational events themselves may be different in any given lesion. Even though knowledge of the molecular events leading to the development of carcinoma of the colon is quite extensive, it would be difficult to say, with any degree of confidence, where the point of no return in this pathway lies. There have been studies in which adenomas have been followed, without intervention, for up to 14 years before an invasive event has occurred1, and so it might be considered appropriate that the adenoma be considered the point of no return. But I shall argue that a point of no return, within the concept of carcinogenesis, is a difficult one to accept, certainly within the colon, and also, as we shall see, in the gastric mucosa.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Morson B. President’s Address: the polyp-cancer sequence in the large bowel. Proc Roy Soc Med. 1974;67:451–457.
Williams ED, Lowes AP, Willimas D, Williams GT. A stem cell niche theory of intestinal crypt maintenance based on a study of somatic mutation in colonic mucosa. Am J Pathol. 1992;141:773–776.
Park H-S, Goodlad R, Wright NA. Crypt fission in the small intestine and colon: a mechanism for the emergence of mutagen-induced transformed crypts in mice. Am J Pathol. 1995;146:1416–1427.
Bjerknes M. Expansion of mutant stem cell populations in the human colon. J Theor Biol. 1996;178:381–385.
Wright NA. Stem cell repertoire and the histogenesis of human cancer. J Roy Coll Phys (London) (in press).
Wasan H, Park H-S, Lui KC, Goodlad R, Sasieni P, Bodmer WF, Wright NA. APC in the control of crypt fission. J Pathol (in press)
Wright NA, Alison MR. The Biology of Epithelial Cell Populations. Volt pp 739. Oxford: Clarendon Press.
Fujita S, Hattori T. Cell proliferation, differentiation and migration in the gastric mucosa; a study of the background of carcinogenesis. In Farber E, Sigano H. eds. Pathophysiology of carcinogenesis in digestive organs. Baltimore: University Park Press; 1977:22–31.
Williams T, Bjerknes R. Stochastic model for abnormal clone spread through epithelial basal layers. Nature (Lond) 1972;236:19–21.
Correa P. A human model for gastric carcinogenesis. Cancer Res 1988;48:3554–3560.
Morson BC, Sobin LH, Grundmann E, Johansen A, Nogayo T, Serek-Hanssen A. Precancerous conditions and epithelial dysplasia in the stomach. J Clin Pathol 1980;33:711–721.
Craanen ME, Blok P, Dekker W et al. Chronology of p53 protein accumulation in gastric carcinogenesis. Gut 1995;36:848–852.
Miracco C, Spina D, Vindigni C, Filipe MI, Tosi P. Cell proliferation patterns and p53 in gastric dysplasia. Int J Cancer 1995;62:149–154.
Brito MJ, Williams GT, Thompson H, Filipe MI. Expression of p53 in early (Tl) gastric carcinoma and pre-cancerous adjacent mucosa. Gut 1994;35:1697–1700.
Joypaul PV, Newman EL, Hopwood D, Grant A, Qureshi S, Lane DP, Cushieri A. Expression of p53 protein in normal, dysplastic and malignant gastric mucosa: an immunohistochemical study. J Pathol 1993;170:279–283.
Rhyu MG, Park WS, Jung YJ, Choi SW, Meltzer SJ. Allelic deletions of MCCIAPC and p53 are frequent late events in human gastric carcinogenesis. Gastroenterology 1994;106:15841588.
Sanz-Ortega J, Sanz-Esperona J, Caldes T, Gomez de la Concha E, Sobel ME, Merino MJ. LOH at the APC/MCC gene (5Q21) in gastric cancer and pre-neoplastic lesions. Pathol Res Pract 1996;192:1206–1210.
Tahara E. Molecular biology of gastric cancer. World J Surg. 1995;19:484–488.
Tahara E, Yokohazi H, Yasui W. Growth factors in gastric cancer. In Nishi M, Ichikawa H, Nakajima T, Maruyama K, Tahara E, eds. Gastric Cancer. Tokyo: Springer Verlag; 1994:207–217.
Ochiai A, Yamanchi Y, Hirohashi S. p53 mutations in the non-neoplastic mucosa of the human stomach showing intestinal metaplasia. Int J Cancer 1996;69:28–33.
Gomyo Y, Osaki M, Kaibara N, Ho H. Numerical aberration and point mutation of p53 in human gastric intestinal metaplasia and well-differentiated adenocarcinoma: analysis of fluorescence in situ hybridisation (FISH) and PCR-SSCP. Int J Cancer. 1996;66:594–599.
Kuipers EJ, Perez-Perez CH, Meuwissen SJ, Balser MJ. Helicobacter pylori and chronic gastritis: importance of the CagA status. J. Natl Cancer Inst. 1995;87:1777–1780.
Bukin YV, Draudin-krylenko VA, Kurshinaov YP, Poddubnij BK, Shabanov MA. Decrease of ornithine decarboxylase activity in premalignant gastric mucosa and regression of intestinal metaplasia in patients supplemented with high doses of vitamin E. Cancer Epidemiol Biomarkers Prey. 1997;6:543–546.
Farinati F, Rugge M, Di Mario F, Valiante F, Batta R. Early and advanced gastric cancer in the follow-up of moderate and severe gastric dysplasia. A prospective study. Endoscopy. 1993;25:261–264.
Digregio C, Morandi P, Fante R, Gaetani C. Gastric dysplasia: a follow-up study. Am J Gastroenterol. 1993;88:1714–1719.
Bearzi I, Brancorsini D, Santinelli A, Rezai B, Mannello P, Ranaldi R. Gastric dysplasia: a ten year follow-up study. Pathol Res Pract 1994;190:61–68.
Rugge M, Farinati F, Batta R, et al. Gastric epithelial dysplasia in the natural history of gastric cancer: a multicentre prospective follow-up study. Gastroenterology 1994; 107:12881296.
Reed PI, Hill MJ, Johnston BC. Gastric cancer and H. pylori. Lancet 1993;342:987.
Borody TJ, Clark IW, Andrews P, Hugh TB, Shortis NP. Eradication of H. pylori may not reverse severe gastric dysplasia. Am J Gastroenterol 1995: 90;498–499.
Recavarren-Aece S, Leon-Barua R, Cok J, et al. Helicobacter pylori and progressive gastric pathology that predisposes to gastric cancer. Scand J Gastroenterol. 1991;26(Supp1181):51–57.
Genta RM, Lew GM, Graham DY. Change in the gastric mucosa following eradication of Helicobacter pylori. Mod Pathol. 1993;6:281–289.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Wright, N.A. (1998). Gastric carcinogenesis: when is the point of no return?. In: Hunt, R.H., Tytgat, G.N.J. (eds) Helicobacter pylori. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-4882-5_35
Download citation
DOI: https://doi.org/10.1007/978-94-011-4882-5_35
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-6046-2
Online ISBN: 978-94-011-4882-5
eBook Packages: Springer Book Archive